5-phenylpent-2-en-4-ynoic acid | 91136-44-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-phenylpent-2-en-4-ynoic acid
• 英文别名: 5-Phenylpent-2-en-4-ynoic acid
• CAS: 91136-44-6
• 化学式: C₁₁H₈O₂
• 分子量: 172.183
• InChiKey: AAZIWQIHCVVUKB-UHFFFAOYSA-N

物化性质

• 沸点：
  318.5±34.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-二苯乙烯 、 5-phenylpent-2-en-4-ynoic acid 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以90%的产率得到3,3-diphenyl-2-(phenylethynyl)cyclobutyl-1-carboxylic acid
  参考文献：
  名称：

  一种可见光催化[2+2]反应构筑四元环的方法

  摘要：

  本发明公开一种可见光催化[2+2]反应构筑四元环的方法，包括以下步骤：1.1)将不饱和双键化合物和光敏剂加入溶剂中，得到溶液A；1.2)在氩气环境下，用可见光照射溶液A，得到自身二聚[2+2]环丁烷产物；或2.1)将不饱和双键化合物、苯乙烯类化合物和光敏剂加入溶剂中，得溶液B；2.2)在氩气环境下，用可见光照射溶液B，得到交叉的[2+2]环丁烷产物。本发明首次利用可见光敏化剂，实现非刚性双键的分子间[2+2]环化反应；本发明中光敏剂用量小，反应在氩气环境下利用可见光或者太阳光照射就可以实现，反应条件温和；整个过程简洁，高效，体现了其在有机反应和工业生产中的潜在应用。

  公开号：

  CN108623425B

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• Aminohydroxylation of Olefins
  申请人：The Scripps Research Institute

  公开号：US06350905B1

  公开（公告）日：2002-02-26

  Osmium-catalyzed aminohydroxylation reactions are accelerated and expanded in scope by the use of olefinic substrates having ionic groups, either anionic or cationic. The use of ionic groups on olefinic substrates also extends the aminohydroxylatable positions of unsaturations to include &agr;,&bgr;, &bgr;,&ggr;, and &ggr;,&dgr; positions, with respect to such ionic groups. A mechanism for the disclosed acceleration and extension is provided.

  铂催化的氨羟基化反应通过使用具有离子基团的烯烃底物（无论是阴离子还是阳离子）而得到加速和扩展。在烯烃底物上使用离子基团还将氨羟基化位置扩展到与这些离子基团相关的α，β，β，γ和γ，δ位置。提供了所述加速和扩展的机制。
• Methods of 1,3-enyne preparation using copper (I) catalysts
  申请人：Venkataraman Dhandapani

  公开号：US20050255575A1

  公开（公告）日：2005-11-17

  A copper(I) bi-dentate ligand complex-catalyzed procedure for synthesis of 1,3-enynes. The methods and/or systems of this invention afford a variety of enynes, tolerate a variety of sensitive functional groups, and can be employed without resort to expensive palladium reagents.

  一种铜（I）双叉配体络合物催化合成1,3-炔烃的方法。本发明的方法和/或系统可以产生各种不同的炔烃，耐受各种敏感的官能团，并且不需要使用昂贵的钯试剂。
• CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20110105572A1

  公开（公告）日：2011-05-05

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is a C 5-20 heteroaryl or C 5-20 carboaryl group and is optionally substituted; Q 1 is a C 2-7 alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R 1 )C(═O)— or —C(═O)N(R 1 )—; R 1 is hydrogen, C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; and, Q 2 is C 1-7 alkylene, C 5-20 arylene, C 5-20 arylene-C 1-7 alkylene, or C 1-7 alkylene-C 5-20 arylene having a backbone of at least 3 carbon atoms, and is optionally substituted; and pharmaceutically acceptable salts thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to treat proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，并具有以下公式：其中：A是C5-20杂环芳基或C5-20羰基芳基基团，并可选择性地取代；Q1是具有至少2个碳原子的C2-7烷基链，可选择性地取代；J是-N（R1）C（═O）-或-C（═O）N（R1）-；R1是氢，C1-7烷基，C3-20杂环芳基或C5-20芳基；Q2是具有至少3个碳原子的C1-7烷基链，C5-20芳基链，C5-20芳基链-C1-7烷基链，或C1-7烷基链-C5-20芳基链，并可选择性地取代；以及其药学上可接受的盐。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物在体内外抑制HDAC，例如治疗增殖性疾病，如癌症和牛皮癣。
• Crosslinkable Aromatic Polyester
  申请人：Ticona LLC

  公开号：US20140088247A1

  公开（公告）日：2014-03-27

  A crosslinkable aromatic polyester that is formed by polymerizing certain precursor monomers in the presence of a biaromatic crosslinking agent is provided. The crosslinkable aromatic polyester can have a relatively high melting temperature. For example, the melting temperature of the crosslinkable polyester may be from about 200° C. to about 370° C. While having a relatively high melting temperature, the crosslinkable polyester can maintain a relatively low melt viscosity so that it can be readily removed from the polymerization reactor without solidifying therein.

  提供了一种可交联的芳香族聚酯，它是通过在双芳香交联剂存在下聚合某些前体单体形成的。可交联的芳香族聚酯可以具有相对较高的熔点。例如，可交联聚酯的熔点可以从约200°C到约370°C。虽然具有相对较高的熔点，但可交联聚酯可以保持相对较低的熔融粘度，以便可以轻松地从聚合反应器中移除，而不会在其中凝固。